![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, July 13, 2023 9:38:02 PM
Price: 30.25, Change: +4.45, Percent Change: +17.25
ACADIA Pharmaceuticals Acquires Ex-North America Rights to Trofinetide, Global Rights to NNZ-2591; Shares Rise After Hours
2023-07-13 05:26:11 PM ET (MT Newswires)
05:26 PM EDT, 07/13/2023 (MT Newswires) -- ACADIA Pharmaceuticals (ACAD) said Thursday it expanded its current licensing agreement for trofinetide, a treatment for Rett syndrome, with Neuren Pharmaceuticals to acquire ex-North American rights to the drug.
The agreement also gives Acadia global rights to Neuren's NNZ-2591 in Rett syndrome and Fragile X syndrome.
Under the agreement, Neuren will receive an upfront payment of $100 million and may receive potential downstream milestone and royalty payments earned separately for trofinetide and NNZ-2591.
Outside of North America, Neuren may receive additional payments for trofinetide upon the achievement of certain revenue milestones and it will also get tiered royalties from the mid-teens to low-twenties percent of trofinetide sales.
Potential future payments to Neuren related to NNZ-2591 in Rett syndrome and Fragile X syndrome are equal to the payments for trofinetide in each of North America and outside North America, Acadia said.
Acadia said it plans to submit a new drug submission for trofinetide in Canada in the next 18 months. It will announce plans for Europe, Asia and other regions at a later date.
Shares of Acadia climbed 17% in after-hours trading Thursday.
Price: 30.25, Change: +4.45, Percent Change: +17.25
Recent ACAD News
- Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting • Business Wire • 06/18/2024 01:04:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 10:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 10:00:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 10:00:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 10:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 10:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 10:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 08:10:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 09:23:31 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/29/2024 08:55:27 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/29/2024 08:54:27 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/29/2024 08:53:56 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/29/2024 08:53:28 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/29/2024 08:53:27 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/29/2024 08:53:24 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/29/2024 08:53:09 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/29/2024 08:53:02 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/29/2024 08:02:29 PM
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/17/2024 08:05:00 PM
- Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome • Business Wire • 05/15/2024 01:05:00 PM
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences • Business Wire • 05/09/2024 08:58:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:10:16 PM
- Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview • Business Wire • 05/08/2024 08:05:00 PM
- Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship • Business Wire • 04/29/2024 08:16:00 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM